within Pharmacolibrary.Drugs.ATC.B;

model B03XA04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0050999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0024,
    k12             = 0.185,
    k21             = 0.185
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03XA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Peginesatide is a synthetic, pegylated peptide-based erythropoiesis-stimulating agent (ESA) designed to stimulate erythropoiesis by binding to and activating the erythropoietin receptor. It was previously used for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Due to safety concerns, including cases of severe hypersensitivity reactions, peginesatide was withdrawn from the market and is not currently approved or in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were primarily characterized in adult CKD patients undergoing dialysis. Peginesatide exhibits nonlinear pharmacokinetics typical of large, pegylated molecules.</p><h4>References</h4><ol><li><p>Woodburn, KW, et al., &amp; Tagawa, Y (2013). Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 41(4) 774–784. DOI:<a href=&quot;https://doi.org/10.1124/dmd.112.048033&quot;>10.1124/dmd.112.048033</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23318685/&quot;>https://pubmed.ncbi.nlm.nih.gov/23318685</a></p></li><li><p>Naik, H, et al., &amp; Vakilynejad, M (2013). A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. <i>PloS one</i> 8(6) e66422–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0066422&quot;>10.1371/journal.pone.0066422</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23840463/&quot;>https://pubmed.ncbi.nlm.nih.gov/23840463</a></p></li><li><p>Czerniak, R, et al., &amp; Qiu, P (2014). Effects of Peginesatide Injection on QTc Interval in Healthy Adults. <i>Clinical pharmacology in drug development</i> 3(6) 449–455. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.141&quot;>10.1002/cpdd.141</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26161294/&quot;>https://pubmed.ncbi.nlm.nih.gov/26161294</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03XA04;
